Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat

STOCKHOLM, June 17, 2026 /PRNewswire/ — Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical…

Read the full release →

News provided by PR Newswire.